Sigma Receptor-Mediated Alterations in Cellular Morphology and Viability

Total Page:16

File Type:pdf, Size:1020Kb

Sigma Receptor-Mediated Alterations in Cellular Morphology and Viability The Journal of Neuroscience, January 1995. 75(l): 117-134 Cytotoxic E ffects of Sigma Ligands: Sigma Receptor-mediated Alterations in Cellular Morphology and Viability Bertold J. Vilner, Brian Ft. de Costa, and Wayne D. Bowen Unit on Receptor Biochemistry and Pharmacology, Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892 The morphological effects of several neuroleptics as well as effect on the activity of sigma compounds. Increasing the other novel and prototypic sigma ligands were examined by pH from the normal range of 7.2-7.4 to pH 8.3-8.5 shifted addition to cultures of C6 glioma cells. Sigma ligands caused the dose curves (30, 100,300 NM) for all sigma compounds loss of processes, assumption of spherical shape, and ces- to the left. Under these conditions, DTG, (+)-3-PPP, and ben- sation of cell division. The time course and magnitude of zomorphans produced effects in 24 hr or less. Decreasing this effect were dependent on the concentration of sigma the medium pH to 6.5-6.7 markedly reduced the activity of ligand. Continued exposure to sigma compounds ultimately all sigma ligands, producing significant protection from cy- resulted in cell death. However, the morphological effect was totoxic effects. Importantly, compounds that lacked sigma reversible when sigma ligand was removed shortly after binding affinity showed neither synergism with 30 PM BD737 rounding. The potency of compounds to produce these ef- nor an increase in activity at higher pH. These results confirm fects generally correlated with binding affinity at sigma re- the sigma receptor specificity of this effect. Sigma ligands ceptors of C6 glioma cell membranes labeled with [3H](+)- had similar effects on other cells of neuronal and non-neu- pentarocine. At a concentration of 100 PM, haloperidol, ronal origin, including SK-N-SH and SH-SY5Y neuroblasto- reduced haloperidol, fluphenazine, perphenazine, trifluo- mas, NCB-20 hybridoma, NG 108- 15 neuroblastoma-glioma perazine, BD737, LR172, BD1006, and SH344 produced sig- hybrid, COS-7 (kidney), MRS-5 (lung), and PC12 pheochrom- nificant effects in 3-6 hr of exposure. Other compounds, ocytoma. These results suggest that sigma receptors play such as trifluperidol, thioridazine, and (-)-butaclamol, pro- some vital role in cell function and may have important im- duced significant effects by 24 hr of exposure. Despite the plications for neurodegenerative disorders and neuroleptic requirement of micromolar concentrations of ligand (some treatment. compounds were effective at 30 PM), the effect showed a [Key words: sigma receptors, neurolepfics, cytotoxicity, remarkable specificity for compounds exhibiting sigma re- neurodegeneration, C6 glioma, haloperidol] ceptor binding affinity. Neuroleptics lacking potent sigma affinity [e.g., (-)-sulpiride, (+)-butaclamol, and clozapine] Sigma receptorsare saturable, high-affinity binding sitesfor sev- and other compounds that lack significant sigma affinity but eral important classesof psychotropic drugs, and have received that are agonists or antagonists at dopamine, serotonin, ad- intensive study in recent years (Musacchio et al., 1989a;Itzhak renergic, glutamate, phencyclidine, GABA, opiate, or mus- and Stein, 1990; Walker et al., 1990, 1993b; Ferris et al., 1991; carinic cholinergic receptors were without effect on cellular Su, 1991; Bowen, 1993; Debonnel, 1993). These receptors are morphology at concentrations up to 300 PM over a period of distinct in pharmacologicalprofile, tissuedistribution, and sub- 72 hr. Likewise, blockers and activators of Na+, K+, and Ca2+ cellular localization from any known neurotransmitter or hor- channels and a monoamine oxidase inhibitor devoid of mone receptor. Sigma sitesare located not only in the CNS, but sigma affinity were without effect. Interestingly, 1,3-di-etolyl- also occur in high density in severalperipheral tissues,including guanidine (DTG), (+)-3-(3-hydroxyphenyI)-N-( 1 -pro- liver and endocrine tissuesuch as testis and ovary. At least two pyl)piperidine [( +)3-PPP], (+)-pentazocine, (+)-cyclazo- classesof sigma sites, termed sigma-l and sigma-2,have been tine, and other sigma-active benzomorphans and morphinans identified (Walker et al., 1990; Quirion et al., 1992). These sites appeared inactive in up to 72 hr of culture. However, these are distinguishable by their affinity for dextrorotatory benzo- compounds interacted synergistically with a subeffective morphans and by molecular size (Hellewell and Bowen, 1990; dose of BD737 (30 AM) to produce effects usually in 6 hr or Di Paolo et al., 1991; Bowen et al., 1993; Hellewell et al., 1994. less. Also, the pH of the culture medium had a profound Though the exact role of sigma receptors in synaptic transmis- sion and cell function is still largely unknown, sigmasites have Received Dec. 3 I, 1993; revised Apr. 20, 1994; accepted June 9, 1994. been implicated in a number of biochemical, physiological, and We acknowledge Dr. F. 1. Carroll, Research Triangle Institute, and Dr. Kenner behavioral processesincluding motor control, neurotransmitter C. Rice, NIDDK, for providing some of the opiate-related compounds used in synthesisand release,ileal smooth musclecontraction, duodenal this study. We also acknowledge Dr. Xiao-shu He, NIDDK, for the synthesis of SH322, SH344, and SH384. bicarbonate secretion,and modulation of muscarinicand N-me- Correspondence should be addressed to Wayne D. Bowen, Ph.D., Chief, Unit thyl-D-aspartate (NMDA) receptor function (Walker et al., 1990, on Receptor Biochemistry and Pharmacology, Laboratory of Medicinal Chem- 1993b; Bowen, 1993; Debonnel, 1993). istry, NIDDK, Building 8, Room BI-23, 9000 Rockville Pike, Bethesda, MD 20892. Much of the initial interest in sigma siteshas stemmedfrom Copyright 0 1995 Society for Neuroscience 0270-6474/95/150117-18$05.00/O their high affinity for most of the typical antipsychotic drugs. 118 Vilner et al. Sigma Receptor-mediated Morphologic and Cytotoxic Effects Among these are haloperidol, fluphenazine, and perphenazine. 44 mM sodium bicarbonate and 10% fetal bovine serum (FBS) (Ad- In view of this, sigma sites have been implicated in the etiology vanced Biotechnologies, Inc., Columbia, MD) in 24-well plastic plates (Costar, Cambridge, MA) in a humidified atmosphere of 5% CO,/95% of psychosis and have been viewed as an alternative target to air (normal conditions, pH 7.2-7.4). For all drug additions, FBS was dopamine D, receptors for antipsychotic drug design. Because reduced from 10% to 1%. Where specified, the pH of culture medium sigma receptors occur in very high density in motor regions of was altered from normal during treatment of cells with drugs. For al- the brain, such as brainstem motor nuclei, substantia nigra, and kaline conditions (pH 8.3-8.5), cells were cultured in the above medium cerebellum, sigma sites have also been proposed to contribute in humidified air only. This was accomplished by placing plates inside of a sealed desiccator that contained normal room air and water (for to the untoward motor side effects resulting from acute and humidity), and maintaining the desiccator at 37°C inside ofan incubator. chronic neuroleptic treatment (Walker et al., 1988). Consistent For acidic conditions (pH 6.5-6.7) cells were cultured in humidified 5% with this, microinjection of haloperidol, 1,3-di-o-tolylguanidine CO,/95%air in eitherDulbecco’s phosphate-buffered saline (Life Tech- (DTG), (+)-pentazocine, and other sigma ligands into the rat nologies, Inc.-GIBCO BRL, Grand Island, NY) supplemented with l- 2% FBS or L-l 5 medium (GIBCO-Bethesda Research Labs, Grand red nucleus causes acute dystonic reactions, reminiscent of the Island, NY) supplemented with 1% FBS, both without sodium bicar- acute reactions observed in patients receiving neuroleptic treat- bonate. Cells were preplated 1-2 d before the start of the experiment, ment (Walker et al., 1988; Matsumoto et al., 1990). In the course at a density of 5-6 x lo3 or 1 x IO4 cells/cm’ to avoid contact inhibition of investigating the behavioral effects of haloperidol and its of dividing cells during the 3 d observation period. metabolites by microinjection into the red nucleus of the rat, SK-N-SH human neuroblastoma (ATCC, Rockville, MD), SH-SYSY subclone of SK-N-SH (from Dr. Tommaso Costa, NICHD/NIH, Be- we discovered that reduced haloperidol, a major metabolite and thesda, MD), NCB-20 mouse neuroblastoma x Chinese hamster brain potent sigma ligand, was neurotoxic (Bowen et al., 1990). The hybrid (from Dr. Richard Miller, University of Chicago, Chicago, IL), compound caused extensive gliosis and loss of magnocellular NG 1 OS- I5 mouse neuroblastoma x rat glioma hybrid (from Dr. Rich- neurons in and around the area of microinjection. These patho- ard Weber, NIDDK, Bethesda, MD), COS-7 African green monkey SV- transformed kidney (ATCC, Rockville, MD), and MRS-5 human lung, logic changes were accompanied by long-lasting (> 3 d) postural diploid, x-irradiated (ATCC, Rockville, MD), were cultured as de- abnormalities. Similar results were observed with BD614, a scribed above for C6 glioma cells. PC1 2 pheochromocytoma were cul- novel and highly selective sigma ligand (Bowen et al., 1992). It tured in RPM1 I640 (Siama- Chemical Co.. St. Louis. MO1, SuDDlemented. was difficult, initially, to link these effects with action at sigma with 23 mM sodium bicarbonate, 10% horse serum (Advanced Bio- receptors since other sigma ligands tested had produced only technologies, Inc.), and 5% fetal
Recommended publications
  • (125I)Iodoazidococaine, a Photoaffinity Label for the Haloperidol-Sensitive Sigma Receptor (Cocaine/[3H]Cocaine Binding/Cocaine-Binding Protein) JOHN R
    Proc. Natl. Acad. Sci. USA Vol. 89, pp. 1393-1397, February 1992 Biochemistry (125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor (cocaine/[3H]cocaine binding/cocaine-binding protein) JOHN R. KAHOUN AND ARNOLD E. RuOHO* Department of Pharmacology, University of Wisconsin Medical School, Madison, WI 53706 Communicated by James A. Miller, October 8, 1991 (received for review July 10, 1991) ABSTRACT A carrier-free radioiodinated cocaine photo- cifically block the photolabeling ofthe DA transporter, it was affinity label, (-)-3-('25I)iodo-4-azidococaine [('25I)IACoc], not established whether cocaine bound directly to this protein has been synthesized and used as a probe for cocaine-binding or to an associated protein. Recently, the human NE trans- proteins. Photoaffinity labeling with 0.5 nM ('25I)IACoc re- porter has been expression-cloned as cDNA and overex- sulted in selective derivatization of a 26-kDa polypeptide with pressed in HeLa cells (13). The ability of cocaine to block the pharmacology of a sigma receptor in membranes derived [3H]NE uptake into these HeLa cells provides good evidence from whole rat brain, rat liver, and human placenta. Covalent that cocaine binds directly with this transporter. labeling of the 26-kDa polypeptide was inhibited by 1 FM Although cocaine has been shown to block the binding of haloperidol, di(2-tolyl)guanidine (DTG), 3-(3-hydroxyphenyl)- sigma ligands to rat and guinea pig brain membranes with N-(1-propyl)piperidine (3-PPP), dextromethorphan, and car- relatively low affinity, the nature and physiological impor- betapentane. Stereoselective protection of (125I)IACoc photo- tance of this interaction is not known.
    [Show full text]
  • Docteur» at the University François Rabela
    UNIVERSITÉ FRANÇOIS – RABELAIS DE TOURS École Doctorale « Santé - Sciences Biologiques - Chimie du Vivant » and UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY «Department of Pharmaceutical Chemistry» A cotutelle thesis submitted in fulfillment of the requirements for the degree of «Docteur» at the University François Rabelais of Tours (France) and Doctor of Pharmacy at the University of Ljubljana (Slovenia) In Pharmaceutical Chemistry Publicly defended on the 1st of March 2013 by Mitja KOVAČ in Ljubljana FLUORATION DE DERIVES DU BENZOVESAMICOL POUR L'OBTENTION DE RADIOLIGANDS POTENTIELS DU TRANSPORTEUR VESICULAIRE DE L'ACETYLCHOLINE Under the co-direction of: Associate Professor Sylvie Mavel (MCU, Tours) and Associate Professor Marko Anderluh (Ljubljana) ----------------- JURY for Oral Defense: Ms MAVEL Sylvie – Associate Professor, University François-Rabelais, Tours, France Mr ANDERLUH Marko – Associate Professor, University of Ljubljana, Slovenia Mr DOLLÉ Frédéric – Service Hospitalier Frédéric Joliot, Institut d'Imagerie BioMédicale - CEA, Orsay, France (Reviewer) Mr EMOND Patrick – Professor, University François-Rabelais, Tours, France Ms GMEINER STOPAR Tanja – Assistant Professor, University of Ljubljana, Slovenia (Reviewer) Mr GOBEC Stanislav – Professor, University of Ljubljana, Slovenia (Chairman) This cotutelle PhD was carried out with the collaboration between the University of Tours (Laboratoire de Biophysique Médicale et Pharmaceutique, Unité INSERM U930 - FRANCE) and the University of Ljubljana (Faculty of Pharmacy, Department of Pharmacutical Chemistry - SLOVENIA). The work was supported by a grant from the Slovene Human Resources Development and Scholarship Fund, by a grant from the University of Ljubljana (Inovativna shema za sofinanciranje doktorskega študija za spodbujanje sodelovanja z gospodarstvom in reševanja aktualnih družbenih izzivov - generacija 2010 Univerza v Ljubljani), and by a Slovenia- French bilateral collaboration project (project n° BI-FR/12-13-PROTEUS-007).
    [Show full text]
  • The Pharmacologist 2 0 0 6 December
    Vol. 48 Number 4 The Pharmacologist 2 0 0 6 December 2006 YEAR IN REVIEW The Presidential Torch is passed from James E. Experimental Biology 2006 in San Francisco Barrett to Elaine Sanders-Bush ASPET Members attend the 15th World Congress in China Young Scientists at EB 2006 ASPET Awards Winners at EB 2006 Inside this Issue: ASPET Election Online EB ’07 Program Grid Neuropharmacology Division Mixer at SFN 2006 New England Chapter Meeting Summary SEPS Meeting Summary and Abstracts MAPS Meeting Summary and Abstracts Call for Late-Breaking Abstracts for EB‘07 A Publication of the American Society for 121 Pharmacology and Experimental Therapeutics - ASPET Volume 48 Number 4, 2006 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. The Editor PHARMACOLOGIST Suzie Thompson EDITORIAL ADVISORY BOARD Bryan F. Cox, Ph.D. News Ronald N. Hines, Ph.D. Terrence J. Monks, Ph.D. 2006 Year in Review page 123 COUNCIL . President Contributors for 2006 . page 124 Elaine Sanders-Bush, Ph.D. Election 2007 . President-Elect page 126 Kenneth P. Minneman, Ph.D. EB 2007 Program Grid . page 130 Past President James E. Barrett, Ph.D. Features Secretary/Treasurer Lynn Wecker, Ph.D. Secretary/Treasurer-Elect Journals . Annette E. Fleckenstein, Ph.D. page 132 Past Secretary/Treasurer Public Affairs & Government Relations . page 134 Patricia K. Sonsalla, Ph.D. Division News Councilors Bryan F. Cox, Ph.D. Division for Neuropharmacology . page 136 Ronald N. Hines, Ph.D. Centennial Update . Terrence J. Monks, Ph.D. page 137 Chair, Board of Publications Trustees Members in the News .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Role for Sigma Receptors in Stimulant Self Administration and Addiction
    Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Current Biological Treatments of Schizophrenia
    Schizophrenia Block Adapted from the American Society for Clinical Psychopharmacology Model Curriculum * Learning Objectives • Identify major target symptoms of schizophrenia treatment • Become familiar with conventional & atypical antipsychotic medications • Recognize major side effects of antipsychotic medications • Recognize unique features of clozapine & depot antipsychotics Outline • Background about Schizophrenia • Dopamine Hypothesis • Dopamine Pathways • Efficacy of Anti-psychotics • Treats agitation • Prevents relapse • Compliance, Medication dose & relapse • Overview of an Antipsychotic Medication Trial • Different Anti-psychotic medications • Side effects of the Anti-psychotics • Common-EPS, TD, anti-cholinergic, metabolic syndrome, • Rare but serious-NMS • Antipsychotic selection and treatment strategies algorithm Dopamine Hypothesis of Schizophrenia Dopamine Hypothesis • Psychotic symptoms can be induced by dopamine agonists* • cocaine, amphetamines cause psychosis • All anti-psychotics are dopamine antagonists • Normal subjects-10% dopamine receptors occupied at baseline** • Schizophrenic subjects-20% dopamine receptors occupied at baseline** **Laruelle M, Quart J Nuc Med 1998;42:211 * Major Dopamine Pathways 1. Nigrostriatal tract- (extrapyramidal pathway) substantia nigra to caudate nucleus & putamen of the basal ganglia 2. Mesolimbic tract - midbrain tegmentum to nucleus accumbens & adjacent limbic structures 3. Mesocortical tract - midbrain tegmentum to anterior cortical areas 4. Tuberoinfundibular tract - arcuate &
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub
    US 2003.0171347A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub. Date: Sep. 11, 2003 (54) SIGMA RECEPTOR ANTAGONISTS HAVING Publication Classification ANT-COCANE PROPERTIES AND USES THEREOF (51) Int. Cl." ......................... A61K 31/55; A61K 31/33; A61K 31/397; A61K 31/445; (76) Inventor: Rae R. Matsumoto, Edmond, OK (US) A61K 31/40; A61K 31/137 (52) U.S. Cl. .............. 514/183; 514/210.01; 514/217.12; Correspondence Address: 514/317; 514/408; 514/649 DUNLAP, CODDING & ROGERS PC. PO BOX 16370 OKLAHOMA CITY, OK 73114 (US) (57) ABSTRACT (21) Appl. No.: 10/178,859 The present invention relates to novel Sigma receptor antagonist compounds that have anti-cocaine properties. (22) Filed: Jun. 21, 2002 These Sigma receptor antagonists are useful in the treatment Related U.S. Application Data of cocaine overdose and addiction as well as movement disorders. The Sigma receptor antagonists of the present (63) Continuation of application No. 09/715,911, filed on invention may also be used in the treatment of neurological, Nov. 17, 2000, now abandoned, which is a continu psychiatric, gastrointestinal, cardiovascular, endocrine and ation of application No. 09/316,877, filed on May 21, immune System disorders as well as for imaging procedures. 1999, now abandoned. The present invention also relates to novel pharmaceutical compounds incorporating Sigma receptor antagonists which (60) Provisional application No. 60/086,550, filed on May can be used to treat overdose and addiction resulting from 21, 1998. the use of cocaine and/or other drugs of abuse.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • Design & Synthesis of Polycyclic Amine Derivatives for Sigma Receptor Activity
    UNIVERSITY OF THE WESTERN CAPE Design & Synthesis of Polycyclic Amine derivatives for Sigma Receptor Activity Natasha Strydom February 2013 Supervisor: Prof. S.F. Malan Co-Supervisor: Dr. J. Joubert A thesis submitted in partial fulfilment of the requirements for the degree of Magister Scientiae in the Department of Natural Sciences, University of the Western Cape. KEYWORDS Polycyclic amine Pentacycloundecane Amantadine Heterocyclic amines Sigma receptor Neurodegeneration Drug addiction Blood brain permeability Drug Design Ligand based Structure activity relationship i ABSTRACT New therapeutic strategies are needed for a diverse array of poorly understood neurological impairments. These include neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease, and the psychiatric disorders such as depression, anxiety and drug dependence. Popular neuropharmacotherapies have focused on dopamine (DA), serotonin (5HT), γ-aminobutric acid (GABA) and glutamate systems (Jupp & Lawrence, 2010). However recent research points to the sigma receptor (σR) as a possible neuromodulatory system. Due to its multi-receptor action, the σR can trigger several significant biological pathways. This indicates its ideal potential as a drug target to effectively minimise drug dosage and potential side effects. Currently there are a limited number of σR ligands available and few possess the selectivity to significantly show σR’s role in neurological processes. Polycyclic amines have shown notable sigma activity and provide an advantageous scaffold for drug design that can improve pharmacodynamic and pharmacokinetic properties (Banister et al., 2010; Geldenhuys et al., 2005). Aryl-heterocycle amine groups were also shown to improve σR activity (Piergentili et al., 2009). A series of pentacycloundecane compounds were synthesised which aimed at evaluating the inclusion of a amine containing aryl group in the design compared to previous pentacycloundecane structures containing only two lipophilic regions.
    [Show full text]